Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Jounce Therapeutics (NASDAQ: JNCE ) stock jumped after it sold rights to a cancer drug to Gilead Sciences (NASDAQ: GILD ). Shares were trading as high as $1.30 in the pre-market, after closing under 75 cents on Dec. 27.

Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?

Gilead Sciences

Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.

Gilead buys out rights to cancer therapy from Jounce for $67 mln

Jounce Therapeutics Inc. JNCE, -6.66% shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. GILD, +0.31% would completely acquire rights to an immunotherapy drug from Jounce. Gilead said it would buy out its remaining obligations under a licensing agreement executed in 2020 between the two companies and acquire intellectual property and rights to the cancer treatment, known as GS-1811.

Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug

-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- -- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors --

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

FOSTER CITY, Calif. & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020.

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) -

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

Jounce Therapeutics, Inc. (NASDAQ:JNCE ) Q3 2022 Results Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray - Chief Executive Officer and President Hugh Cole - Chief Operating Officer Elizabeth Trehu - Chief Medical Officer Dmitri Wiederschain - Chief Scientific Officer Kim Drapkin - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Boris Peaker - Cowen and Company Edward Tenthoff - Piper Sandler David Dai - SMBC Nikko Yu He - H.C. Wainwright & Co. Colleen Kusy - Robert W.

Jounce Therapeutics, Inc. (JNCE) Q3 2022 Results - Earnings Call Transcript

- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress -

Jounce Therapeutics Reports Third Quarter 2022 Financial Results

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead Sciences, Inc. (NASDAQ: GILD) under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize. GS-1811 (formerly JTX-1811) is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells in the tumor microenvironment.

Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET.

Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

- Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 -

Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate in the following upcoming investor conferences in September:

Jounce Therapeutics to Participate in the Upcoming Investor Conferences

Jounce Therapeutics (JNCE) declines as its mid-stage study, SELECT, evaluating vopratelimab in lung cancer patients, fails to meet the primary endpoint.

Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down

- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks -

Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients

Jounce Therapeutics, Inc. (NASDAQ:JNCE ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray - Chief Executive Officer & President Beth Trehu - Chief Medical Officer Dmitri Wiederschain - Chief Scientific Officer Kim Drapkin - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Boris Peaker - Cowen Steven Seedhouse - Raymond James David Dai - SMBC Swayampakula Ramakanth - HCW Nick Abbott - Wells Fargo Operator Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics Second Quarter -- 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2022 Results - Earnings Call Transcript

- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end -

Jounce Therapeutics Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2022 financial results and provide a corporate update on Thursday, August 4, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET.

Jounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate at the following upcoming investor conferences:

Jounce Therapeutics to Present at Upcoming Investor Conferences

Jounce Therapeutics, Inc. (NASDAQ:JNCE ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Eric Laub - VP, IR Richard Murray - President, CEO & Director Elizabeth Trehu - Chief Medical Officer Kimberlee Drapkin - Chief Financial Officer & Treasurer Dmitri Wiederschain - Chief Scientific Officer Conference Call Participants Boris Peaker - Cowen and Company Steven Seedhouse - Raymond James & Associates Edward Tenthoff - Piper Sandler & Co. Cory Kasimov - JPMorgan Chase & Co. David Dai - SMBC Arthur He - H.C. Wainwright & Co. Nicholas Abbott - Wells Fargo Securities Operator Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics First Quarter 2022 Earnings Conference Call.

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q1 2022 Results - Earnings Call Transcript

- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 -

Jounce Therapeutics Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2022 financial results and provide a corporate update on Thursday, May 5, 2022. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET.

Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer taking place virtually on Tuesday, April 26, 2022 at 1:00 pm ET.

Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray On Q4 2021 Results - Earnings Call Transcript

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Jounce Therapeutics, Inc. (JNCE) Reports Q4 Loss, Lags Revenue Estimates

- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 -

News for Jounce Therapeutics Stock (JNCE)